Epidemiological suggestions that the shingles vaccine might protect against dementia keep rolling in. Pascal Geldsetzer, Stanford University, presented his group’s latest findings at this year’s ...

Is it three steps forward one step back for blood tests? At the 18th Clinical Trials on Alzheimer’s Disease, held December 1–4 in San Diego, new data on the FDA-approved Fujirebio Lumipulse plasma ...

In Pick’s disease, as in Alzheimer’s disease and frontotemporal dementia, tangled tau spells trouble. In this subtype of FTD, abnormal clumps of three-repeat tau called Pick bodies abound in neurons.

Aβ and tau get much of the glory in Alzheimer’s disease, but the disease is far more complex than two proteins. Scientists know, for example, that lipid metabolism goes awry, but identifying ...

Affitope AD02 is a synthetic peptide of six amino acids that mimics the N-terminus of Aβ. AFFiRiS hypothesizes that this fragment enables exclusive recognition of Aβ without cross-reacting with APP, ...

A selected list of scientific conferences relevant to researchers, clinicians and others interested in Alzheimer’s disease and related neurodegenerative disorders.

News Peptide Brace Against AD—Insulin, Neuropeptide Y Tame Aβ Toxicity 10 Feb 2009 Aβ and Phospho-tau: Strange Bedfellows Get Intimate at Synapses 19 Sep 2008 The Skinny on FAT: APP’s Role in Fast ...

The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

In a draft decision, the CMS proposed covering Aduhelm only in clinical trials. Most Alzheimer’s researchers support the proposal. Some challenged its practicality. The manufacturers of the other anti ...

In Europe and the U.S., proportionately fewer people are developing dementia now than in the past. Is this driven by less-prevalent Alzheimer's disease pathology? No, say researchers led by Francine ...